Last edition
News about
Laurus Labs Limited Acquires Stake in Laurus Bio Private Limited
Pursuant to the above acquisition, the stake of the Company in Laurus Bio Private Limited shall reach to 87.58% on fully diluted basis (including outstanding ESOPs and the Share Warrants).
Norgine Appoints Saulo Martiniano as Chief Operating Officer
Saulo joins Norgine with a wealth of experience and a unique blend of leadership, operational expertise, and a deep understanding of manufacturing operational excellence and supply chain.
Aurobindo Pharma's Telangana Plant Classified as VAI by US FDA
Pharmaceutical major Aurobindo Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Unit III in the Bachupally Village, Telangana .
Strides Receives USFDA Approval for Sevelamer Carbonate for Oral Suspension
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Renvela for Oral Suspension, 0.8g and 2.4g of Genzyme.
Natco Pharma, Others Sued in US for Generic Cancer Drug
Natco Pharma said the company and other drug makers have been named defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US.
Lupin's Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is currently the only generic product available that is therapeutically equivalent to Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.
Strides Pharma Science Limited to Acquire 100% in Strides Pharma Services Pvt Ltd
Post the said acquisition, SPSPL shall be a direct WOS of the Company.
US FDA Inspects Aurobindo Pharma's Unit III in Telangana
The Unit has now received an Establishment Inspection Report classifying the facility as 'Voluntary Action Indicated' (VAI).
IndiaRF to Acquire API and CRAMS Business of Ind-Swift Laboratories Limited Worth INR 1,650 Crores
Ind-Swift is amongst the top ten independent merchant API businesses in India in size, with two manufacturing sites in Punjab and Jammu, and a combined reactor capacity of ~700 KL catering to both regulated and unregulated markets.
Schott Seeks More than USD 860 Million in Pharma Unit IPO
Schott Pharma announced plans for a stock sale, consisting of existing shares held by its parent, which will remain the majority shareholder.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy